Saltar al contenido
Merck

Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.

Biochemical and biophysical research communications (2012-10-30)
Yuto Ueda, Shoko Tokashiki, Ai Kanemaru, Toshio Kojima
RESUMEN

The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats with 6-hydoroxydopamine hemiparkinsonism by using a DNA microarray for genome-wide gene expression profiling. We found that the expression of some genes related to metabolism and nervous system development and function were upregulated by zonisamide; expression of these genes was downregulated by levodopa. Furthermore, many genes related to the immune system and inflammation were downregulated by zonisamide, and their expression was upregulated by levodopa. These results indicate that zonisamide has a protective effect when co-administered with levodopa.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Zonisamide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Zonisamide sodium salt, ≥98% (HPLC), powder